Research programme: therapeutic agents - Tasly-SemBioSys
Latest Information Update: 16 Jul 2016
At a glance
- Originator SemBioSys Genetics
- Developer Tasly-SemBioSys Pharmaceuticals
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Diabetes mellitus; Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in China
- 16 Jul 2016 No recent reports of development identified for research development in Diabetes-mellitus in China
- 31 May 2012 Tianjin Tasly Pharmaceutical is now called Tasly Pharmaceutical Group